London, May 16, 2026, 22:06 (BST)
Haleon PLC got a lift Friday while the broader London market dropped. Shares finished at 332.9 pence, up 3.8p or 1.15%, trading about 0.5% higher than last Friday’s close. Volume came in at 23.1 million shares.
London is closed for the weekend, so Friday’s close is the last live price until trading resumes next week. The London Stock Exchange runs regular hours Monday through Friday, 8:00 a.m. to 4:30 p.m. BST.
FTSE 100 drops 1.71% as miners, utilities weigh, sterling sinks The FTSE 100 lost 1.71% to close at 10,195.37 on Friday, pressured by heavy selling in miners and utilities. Sterling slipped and gilt yields pushed higher as investors responded to UK political uncertainty and increased borrowing costs. Haleon managed a gain and was among the FTSE 100 advancers.
The move looked defensive, not like a new company trigger. In markets, a “defensive” stock is one investors buy when they think demand won’t fall much in a downturn. Haleon sells things like toothpaste, painkillers, and non-prescription drugs.
Shareholder returns remained a focus. Haleon handed out a 4.9p final dividend on May 14, paying this from 2025 profits. The company is also in the middle of a £500 million share buyback aimed at cutting or controlling the share count. Haleon Corporate
Haleon canceled 10.2 million ordinary shares, according to a May 11 SEC filing. The shares were purchased between May 5 and May 8. With those shares canceled, Haleon said it now has about 8.87 billion ordinary shares with voting rights.
Haleon stuck to its earlier update. First-quarter organic revenue rose 2.2%, with Oral Health up 8.3% and Respiratory Health down 3.4%. That organic growth figure strips out currency movements and acquisitions. Haleon held its 2026 guidance for organic revenue growth of 3% to 5% and high-single-digit adjusted operating profit growth at constant currency, which ignores exchange rates. CEO Brian McNamara said he sees “growth to accelerate across the balance of the year.” Haleon Corporate
Haleon isn’t set for an earnings release this week. The investor calendar puts H1 numbers out on July 30. Until then, traders are looking at any buyback news, keeping tabs on the sector, and watching the mood across the London market.
Reckitt is seen as the nearest listed peer for this week because of its consumer-health and cold-and-flu exposure. Shares added 1.12% Friday to finish at 4,597p, still under their May 8 close of 4,671p.
But it’s a messy setup. Haleon flagged higher freight costs, a slow cold-and-flu season hurt sales, and demand in the Middle East came in soft. Reuters noted that sluggish cold-and-flu trends also weighed on competitor Reckitt. Quilter’s Chris Beckett summed up the bullish view: “Haleon isn’t a million miles away from being a very good story, but it needs more than the toothpaste business to start performing.” Reuters
Downside risk is clear. If North America stays slow, freight costs climb, or respiratory sales remain weak, Friday’s gain could fade fast and end up looking like a short-lived bounce in a tough London session.
